Ocean Biomedical to develop OCF-203 for pulmonary fibrosis in Hermansky-Pudlak syndrome

April 11, 2023

Ocean Biomedical Inc. announced it will be targeting its pulmonary fibrosis treatment candidate OCF-203 as a novel therapeutic for fatal pulmonary fibrotic conditions caused by Hermansky-Pudlak syndrome (HPS).

BioWorld Science Respiratory

Today's news in brief

BioWorld

BioWorld briefs for July 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 16, 2025.

Illimis $42M series B to spur study of Aβ-clearing fusion protein

BioWorld

Illimis Therapeutics Inc. raised ₩58 billion (US$42 million) in a series B financing round. The funds will support development of ILM-01, its lead bispecific...

Circode applies circRNA to heart disease drug R&D, in vivo CAR T

BioWorld

Shanghai Circode Biomed Co. Ltd. is set to begin clinical trials of HM-2002, a circular RNA (circRNA)-based drug for ischemic heart disease, having gained IND...

Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

BioWorld

The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...